Skip to content

Author

Trong Kha Pham

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

The SGLT2 Inhibitor Empagliflozin Directly Binds Cardiac JNK3, Uncouples c-Jun/c-Fos Signaling, and Confers Cardioprotection in Diabetic Cardiomyopathy.

Background Sodium-glucose cotransporter 2 (SGLT2) inhibitors, including empagliflozin (EMPA), confer significant cardioprotection in type 2 diabetes in addition to lowering glucose levels. However, their direct targets in cardiac tissue and molecular mechanisms underlying their effects in diabetic cardiomyopathy (DCM)...

Trong Kha Pham, H. Nguyen, M. V. F. Garcia et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.